Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
Alimentary Pharmacology & Therapeutics · 2024-06 · 59 (11) · 1413-1424
DOI: 10.1111/apt.17961 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 17.03.2024. Verfasst von Shintaro Akiyama und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background and Aims While filgotinib, an oral Janus kinase (JAK) 1 preferential inhibitor, is approved for moderately to severely active ulcerative colitis (UC), real‐world studies assessing its short‐ and long‐term efficacy and safety are limited.
Methods
This is a multicenter, retrospective study of UC patients who started filgotinib between March 2022 and September 2023. The primary outcome was clinical remission, defined as a partial Mayo score ≤1 with a rectal bleeding score of 0, or Simple Clinical Colitis Activity Index (SCCAI) ≤2 with a blood‐in‐stool score of 0. Secondary outcomes included clinical response, corticosteroid‐free remission, and endoscopic improvement. Outcomes were assessed at 10, 26, and 58 weeks based on patients with available follow‐up. Adverse events were evaluated.
Results
We identified 238 UC patients and 54% had prior exposure to biologics/JAK inhibitors. The median baseline partial Mayo score and SCCAI were 5 (IQR 3–6) and 4 (IQR 2–7). Clinical remission rates based on per‐protocol analysis at 10, 26, and 58 weeks were 47% (70/149), 55.8% (48/86), and 64.6% (31/48), respectively. At a median follow‐up of 28 weeks (IQR 10–54) with a discontinuation rate of 39%, the rates of clinical remission, clinical response, corticosteroid‐free remission, and endoscopic improvement were 39.9% (81/203), 54.7% (111/203), and 36.5% (74/203), and 43.5% (10/23), respectively. These rates were comparable between biologic/JAK inhibitor‐naïve and ‐experienced patients. While three patients (1.3%) developed herpes zoster infection, no cases of thrombosis or death were reported.
Conclusions
Real‐world data demonstrate favourable clinical and safety outcomes of filgotinib for UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
- Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Gastroenterology, Faculty of Medicine, Hyogo Medical University, Hyogo, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
- Center for Inflammatory Bowel Disease, Tokyo Yamate Medical Center, Japan Community Healthcare Organization, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Shintaro Akiyama, Shinichiro Shinzaki, Toshiyuki Sakurai, Shunichi Yanai, Masayuki Saruta, Toshimitsu Fujii
Zitieren
APA
Akiyama, S., Yokoyama, K., Yagi, S., Shinzaki, S., Tsuruta, K., Yoshioka, S., Sako, M., Shimizu, H., Kobayashi, M., Sakurai, T., Nomura, K., Shibuya, T., Takahara, M., Hiraoka, S., Sugai, K., Yanai, S., Yoshida, A., Koroku, M., Omori, T., …, & Fujii, T. (2024). Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan. Alimentary Pharmacology & Therapeutics, 59(11), 1413-1424. https://doi.org/10.1111/apt.17961
Vancouver
Akiyama S, Yokoyama K, Yagi S, Shinzaki S, Tsuruta K, Yoshioka S, et al. Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan. Alimentary Pharmacology & Therapeutics. 2024;59(11):1413-1424. doi:10.1111/apt.17961
BibTeX
@article{Akiyama2024,
author = {Akiyama, Shintaro and Yokoyama, Kaoru and Yagi, Soichi and Shinzaki, Shinichiro and Tsuruta, Kozo and Yoshioka, Shinichiro and Sako, Minako and Shimizu, Hiromichi and Kobayashi, Mariko and Sakurai, Toshiyuki and Nomura, Kei and Shibuya, Tomoyoshi and Takahara, Masahiro and Hiraoka, Sakiko and Sugai, Kyohei and Yanai, Shunichi and Yoshida, Atsushi and Koroku, Miki and Omori, Teppei and Saruta, Masayuki and Matsumoto, Takayuki and Okamoto, Ryuichi and Tsuchiya, Kiichiro and Fujii, Toshimitsu},
title = {Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {11},
pages = {1413--1424},
doi = {10.1111/apt.17961}
}
EUVIMED